OBJECTIVE: This study examined the association between 5-aminolevulinic acid (5-ALA) and glucose tolerance. DESIGN: A double blinded, randomized prospective parallel-group comparison study. SETTING:Participants were recruited from the community in Honolulu, Hawaii, using radio and TV ads, and at community events. PARTICIPANTS: One hundred fifty-four males and females ages 40-70 years, with evidence of prediabetes: hemoglobin A1c (HbA1c) 5.8%-7.0% at the screening visit. INTERVENTION: Participants were randomized equally to one of three study groups: (1) low dose 5-ALA supplement (15 mg capsule); (2) high dose 5-ALA (50 mg capsule); and (3) control (placebo capsule of identical size and color). MAIN OUTCOME MEASURES: HbA1c and 2 hours post-oral glucose tolerance test (OGTT) glucose levels. RESULTS: Among individuals taking 5-ALA supplements for 12 weeks, 2 hours post-OGTT glucose levels declined significantly compared to those not taking the supplement (p= 0.02). The relationships were stronger among those with baseline glucose intolerance, or 2 hours post-OGTT glucose measurements greater than 140 mg/dL (p= 0.005 and p= 0.02 for the low and high dose group, respectively). Similar trends were observed for HbA1c but results were of borderline significance (p= 0.07). No untoward effects were reported. CONCLUSIONS: Further studies are indicated. The potential benefits of 5-ALA dietary supplementation are affirmed by this investigation.
RCT Entities:
OBJECTIVE: This study examined the association between 5-aminolevulinic acid (5-ALA) and glucose tolerance. DESIGN: A double blinded, randomized prospective parallel-group comparison study. SETTING:Participants were recruited from the community in Honolulu, Hawaii, using radio and TV ads, and at community events. PARTICIPANTS: One hundred fifty-four males and females ages 40-70 years, with evidence of prediabetes: hemoglobin A1c (HbA1c) 5.8%-7.0% at the screening visit. INTERVENTION: Participants were randomized equally to one of three study groups: (1) low dose 5-ALA supplement (15 mg capsule); (2) high dose 5-ALA (50 mg capsule); and (3) control (placebo capsule of identical size and color). MAIN OUTCOME MEASURES: HbA1c and 2 hours post-oral glucose tolerance test (OGTT) glucose levels. RESULTS: Among individuals taking 5-ALA supplements for 12 weeks, 2 hours post-OGTT glucose levels declined significantly compared to those not taking the supplement (p= 0.02). The relationships were stronger among those with baseline glucose intolerance, or 2 hours post-OGTT glucose measurements greater than 140 mg/dL (p= 0.005 and p= 0.02 for the low and high dose group, respectively). Similar trends were observed for HbA1c but results were of borderline significance (p= 0.07). No untoward effects were reported. CONCLUSIONS: Further studies are indicated. The potential benefits of 5-ALA dietary supplementation are affirmed by this investigation.
Authors: Roman Ganzer; Andreas Blana; Stefan Denzinger; Wolf F Wieland; Christoph Adam; Armin Becker; Wael Khoder; Sebastian Walther; Christian G Stief; Dirk Zaak; Georg Salomon; Arndt Hartmann; Ruth Knuechel; Simone Bertz; Gralf Popken Journal: J Endourol Date: 2009-09 Impact factor: 2.942
Authors: B L Rodriguez; J D Curb; C M Burchfiel; B Huang; D S Sharp; G Y Lu; W Fujimoto; K Yano Journal: Diabetes Care Date: 1996-06 Impact factor: 19.112
Authors: Dirk Zaak; Ronald Sroka; W Khoder; Christoph Adam; Stefan Tritschler; Alexander Karl; Oliver Reich; Ruth Knuechel; Reinhold Baumgartner; Derya Tilki; Gralf Popken; Alfons Hofstetter; Christian G Stief Journal: Urology Date: 2008-04-11 Impact factor: 2.649
Authors: Noreen L Lyell; Alecia N Septer; Anne K Dunn; Drew Duckett; Julie L Stoudenmire; Eric V Stabb Journal: Appl Environ Microbiol Date: 2017-02-15 Impact factor: 4.792